£
Donate

We're here for you if you want to talk

0808 2080 888

[email protected]

Our partnerships with the pharmaceutical industry

Our partnerships with pharmaceutical companies allow us to deliver vital work supporting people affected by blood cancer.

The support we received in FY20 is detailed below.

Unless otherwise stated, these companies played no part in the organisation, design, or content of any of the work listed.

For more information on how and why we work with the industry, read our Policy on working with pharma.

Janssen

  • £25,000: ‘Living well with blood cancer’ project, providing an online support hub for people affected by blood cancer in the long term. Janssen also supported with monitoring and evaluation expertise
  • £8,663: Report launch – End the Delays
  • £25,000: Evaluation of RDC rollout
  • £6,125: 'Understanding the opportunities to collaborate' project with the Blood Cancer Alliance
  • £2,752: Advisory board

Gilead

  • £25,000: Support Services development

Novartis

  • £52,760: Increasing access to clinical trials project
  • £20,000: Blood Cancer Alliance funding

Celgene

  • £24,000: HCP support

Takeda

  • £20,000: HCP support
  • £17,000: Peer to peer support project
  • £52,760: Increasing access to clinical trials project

AbbVie

  • £10,000: Evaluation of RDC rollout
  • £10,000: Reducing delays to late diagnosis project

Jazz

  • £1,527: Nurses' conference

Sanofi

  • £20,000: HCP support

Amgen

  • £3,000: Grantholders Day conference

Incyte

  • £10,000: Psychological support project

Servier

  • £1,000: Psychological support project
Planning together by Helena Lopes

Get in touch with the Corporate Partnerships Team